Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 10/20 | 0.51 |
| ▸ | GABRD | O14764 | 10/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 10/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 10/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 10/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 10/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 10/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 10/20 | 0.51 |
| ▸ | GABRE | P78334 | 10/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 10/20 | 0.51 |
| ▸ | GABRG1 | Q8N1C3 | 10/20 | 0.51 |
| ▸ | GABRG3 | Q99928 | 10/20 | 0.51 |
| ▸ | GABRQ | Q9UN88 | 10/20 | 0.51 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | HTR1D | P28221 | 3/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2649958 | 0.85 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6305669 | 0.84 | HRH4 (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6306890 | 0.82 | HTR1A (0.45) | HTR1AHTR1DMAPK14HTR1BHPGD | |
| SCHEMBL1761687 | 0.77 | USP2 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6309060 | 0.76 | HTR1A (0.49) | HTR1AHTR1DHTR1B | |
| SCHEMBL6313082 | 0.76 | HTR1A (0.47) | HTR1AHTR1DMAPK14HTR1BMET | |
| SCHEMBL2650164 | 0.75 | GABRP (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2649935 | 0.74 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6754802 | 0.73 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1761837 | 0.71 | GABRA1 (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20050080090-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2005-04-14 | — | — | US | disclosed |
| US-20020058811-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2002-05-16 | — | — | US | disclosed |
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | CHENARD BERTRAND L (US) | 2001-06-21 | — | — | US | disclosed |
| EP-0689536-B1 | NAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-0701819-B1 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5821245-A | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0795328-A1 | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5597826-A | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0701819-A2 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0689536-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021619-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | HTR4, HCRTR2, CNR2 | GABRP 1479/4885GABRD 1741/4885GABRA1 1254/4885 |
| US-20050080090-A1 | Naphthalene derivatives | HTR4, NPY4R, HCRTR1 | GABRP 880/4885GABRD 971/4885GABRA1 772/4885 |
| US-20020058811-A1 | Naphthalene derivatives | HTR4, CNR1, CNR2 | GABRP 1217/4885GABRD 1365/4885GABRA1 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.